Induction prior to autologous haematopoietic cell transplantation in multiple myeloma

被引：0

作者：

Mohty, Mohamad ^{[1
]}

Malard, Florent ^{[1
]}

机构：

[1] Sorbonne Univ, Hop St Antoine, AP HP, Ctr Rech St Antoine,Serv Hematol Clin & Therapie C, Paris, France

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 06期

关键词：

chemotherapy; myeloma; transplantation; DEXAMETHASONE; BORTEZOMIB;

D O I：

10.1111/bjh.19753

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Induction chemotherapy followed by autologous haematopoietic cell transplantation and post-transplant therapy (including maintenance therapy with or without prior consolidation) is still considered as the standard of care for newly diagnosed young and fit multiple myeloma patients. Over the last years, superiority of quadruplet regimens for induction was established, with the addition of an anti-CD38 monoclonal antibody to triplet regimen including a proteasome inhibitor, an IMiD (thalidomide or lenalidomide) or cyclophosphamide, and dexamethasone. Given quadruplet induction regimens are associated with deep response, including a high-rate of sustained measurable residual disease negativity in a significant proportion of patients, they are now recommended for induction chemotherapy when available.

引用

页码：2193 / 2197

页数：5

共 9 条

[1] Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Hulin, Cyrille ;

Leleu, Xavier ;

Caillot, Denis ;

Escoffre, Martine ;

Arnulf, Bertrand ;

Macro, Margaret ;

Belhadj, Karim ;

Garderet, Laurent ;

Roussel, Murielle ;

Payen, Catherine ;

Mathiot, Claire ;

Fermand, Jean P. ;

Meuleman, Nathalie ;

Rollet, Sandrine ;

Maglio, Michelle E. ;

Zeytoonjian, Andrea A. ;

Weller, Edie A. ;

Munshi, Nikhil ;

Anderson, Kenneth C. ;

Richardson, Paul G. ;

Facon, Thierry ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc ;

Moreau, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14) :1311-1320

[2] Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study [J].

Cavo, Michele ;

Tacchetti, Paola ;

Patriarca, Francesca ;

Petrucci, Maria Teresa ;

Pantani, Lucia ;

Galli, Monica ;

Di Raimondo, Francesco ;

Crippa, Claudia ;

Zamagni, Elena ;

Palumbo, Antonio ;

Offidani, Massimo ;

Corradini, Paolo ;

Narni, Franco ;

Spadano, Antonio ;

Pescosta, Norbert ;

Deliliers, Giorgio Lambertenghi ;

Ledda, Antonio ;

Cellini, Claudia ;

Caravita, Tommaso ;

Tosi, Patrizia ;

Baccarani, Michele .

LANCET, 2010, 376 (9758) :2075-2085

[3] Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials [J].

Chhabra, Saurabh ;

Callander, Natalie ;

Watts, Nicole L. ;

Costa, Luciano J. ;

Thapa, Bicky ;

Kaufman, Jonathan L. ;

Laubach, Jacob ;

Sborov, Douglas W. ;

Reeves, Brandi ;

Rodriguez, Cesar ;

Chari, Ajai ;

Silbermann, Rebecca ;

Anderson, Larry D., Jr. ;

Bal, Susan ;

Dhakal, Binod ;

Nathwani, Nitya ;

Shah, Nina ;

Medvedova, Eva ;

Bumma, Naresh ;

Holstein, Sarah A. ;

Costello, Caitlin ;

Jakubowiak, Andrzej ;

Wildes, Tanya M. ;

Schmidt, Timothy ;

Orlowski, Robert Z. ;

Shain, Kenneth H. ;

Cowan, Andrew J. ;

Dholaria, Bhagirathbhai ;

Cornell, R. Frank ;

Jerkins, James H. ;

Pei, Huiling ;

Cortoos, Annelore ;

Patel, Sharmila ;

Lin, Thomas S. ;

Usmani, Saad Z. ;

Richardson, Paul G. ;

Voorhees, Peter M. .

TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (03) :174e1-174e10

[4] Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma [J].

Leypoldt, Lisa B. ;

Tichy, Diana ;

Besemer, Britta ;

Haenel, Mathias ;

Raab, Marc S. ;

Mann, Christoph ;

Munder, Markus ;

Reinhardt, Hans Christian ;

Nogai, Axel ;

Goerner, Martin ;

Ko, Yon-Dschun ;

de Wit, Maike ;

Salwender, Hans ;

Scheid, Christof ;

Graeven, Ullrich ;

Peceny, Rudolf ;

Staib, Peter ;

Dieing, Annette ;

Einsele, Hermann ;

Jauch, Anna ;

Hundemer, Michael ;

Zago, Manola ;

Pozek, Ema ;

Benner, Axel ;

Bokemeyer, Carsten ;

Goldschmidt, Hartmut ;

Weisel, Katja C. .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (01) :26-+

[5] Potential future direction of measurable residual disease evaluation in multiple myeloma [J].

Mohty, Mohamad ;

Avet-Loiseau, Herve ;

Malard, Florent ;

Harousseau, Jean-Luc .

BLOOD, 2023, 142 (18) :1509-1517

[6] Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study [J].

Moreau, Philippe ;

Attal, Michel ;

Hulin, Cyrille ;

Arnulf, Bertrand ;

Belhadj, Karim ;

Benboubker, Lotfi ;

Bene, Marie C. ;

Broijl, Annemiek ;

Caillon, Helene ;

Caillot, Denis ;

Corre, Jill ;

Delforge, Michel ;

Dejoie, Thomas ;

Doyen, Chantal ;

Facon, Thierry ;

Sonntag, Cecile ;

Fontan, Jean ;

Garderet, Laurent ;

Jie, Kon-Siong ;

Karlin, Lionel ;

Kuhnowski, Frederique ;

Lambert, Jerome ;

Leleu, Xavier ;

Lenain, Pascal ;

Macro, Margaret ;

Mathiot, Claire ;

Orsini-Piocelle, Frederique ;

Perrot, Aurore ;

Stoppa, Anne-Marie ;

van de Donk, Niels W. C. J. ;

Wuilleme, Soraya ;

Zweegman, Sonja ;

Kolb, Brigitte ;

Touzeau, Cyrille ;

Roussel, Murielle ;

Tiab, Mourad ;

Marolleau, Jean-Pierre ;

Meuleman, Nathalie ;

Vekemans, Marie-Christiane ;

Westerman, Matthijs ;

Klein, Saskia K. ;

Levin, Mark-David ;

Fermand, Jean Paul ;

Escoffre-Barbe, Martine ;

Eveillard, Jean-Richard ;

Garidi, Reda ;

Ahmadi, Tahamtan ;

Zhuang, Sen ;

Chiu, Christopher ;

Pei, Lixia .

LANCET, 2019, 394 (10192) :29-38

[7] Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma [J].

Rosinol, Laura ;

Oriol, Albert ;

Rios, Rafael ;

Sureda, Anna ;

Jesus Blanchard, Maria ;

Teodoro Hernandez, Miguel ;

Martinez-Martinez, Rafael ;

Moraleda, Jose M. ;

Jarque, Isidro ;

Bargay, Juan ;

Gironella, Mercedes ;

de Arriba, Felipe ;

Palomera, Luis ;

Gonzalez-Montes, Yolanda ;

Marti, Josep M. ;

Krsnik, Isabel ;

Arguinano, Jose M. ;

Esther Gonzalez, Maria ;

Pilar Gonzalez, Ana ;

Felipe Casado, Luis ;

Lopez-Anglada, Lucia ;

Paiva, Bruno ;

Mateos, Maria-Victoria ;

San Miguel, Jesus F. ;

Lahuerta, Juan-Jose ;

Blade, Joan .

BLOOD, 2019, 134 (16) :1337-1345

[8] Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Sonneveld, Pieter ;

Dimopoulos, Meletios A. ;

Boccadoro, Mario ;

Quach, Hang ;

Ho, P. Joy ;

Beksac, Meral ;

Hulin, Cyrille ;

Antonioli, Elisabetta ;

Leleu, Xavier ;

Mangiacavalli, Silvia ;

Perrot, Aurore ;

Cavo, Michele ;

Belotti, Angelo ;

Broijl, Annemiek ;

Gay, Francesca ;

Mina, Roberto ;

Nijhof, Inger S. ;

van de Donk, Niels W. C. J. ;

Katodritou, Eirini ;

Schjesvold, Fredrik ;

Sureda Balari, Anna ;

Rosinol, Laura ;

Delforge, Michel ;

Roeloffzen, Wilfried ;

Silzle, Tobias ;

Vangsted, Annette ;

Einsele, Hermann ;

Spencer, Andrew ;

Hajek, Roman ;

Jurczyszyn, Artur ;

Lonergan, Sarah ;

Ahmadi, Tahamtan ;

Liu, Yanfang ;

Wang, Jianping ;

Vieyra, Diego ;

van Brummelen, Emilie M. J. ;

Vanquickelberghe, Veronique ;

Sitthi-Amorn, Anna ;

de Boer, Carla J. ;

Carson, Robin ;

Rodriguez-Otero, Paula ;

Blade, Joan ;

Moreau, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (04) :301-313

[9] Daratumumab, carfilzomib, fi lzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma [J].

Touzeau, Cyrille ;

Perrot, Aurore ;

Hulin, Cyrille ;

Manier, Salomon ;

Macro, Margaret ;

Chretien, Marie-Lorraine ;

Karlin, Lionel ;

Escoffre, Martine ;

Jacquet, Caroline ;

Tiab, Mourad ;

Leleu, Xavier ;

Avet-Loiseau, Herve ;

Jobert, Alexandra ;

Planche, Lucie ;

Corre, Jill ;

Moreau, Philippe .

BLOOD, 2024, 143 (20) :2029-2036

← 1 →